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Abstract: Intermittent circadian fasting, namely Ramadan, is a common worldwide practice.
Such fasting has a positive impact on psoriasis, but no data exist on its role in psoriatic arthritis
(PsA)—a disease that is clearly linked to body mass index. We enrolled 37 patients (23 females and
14 males) with a mean age 43.32 ± 7.81 and they fasted for 17 h for one month in 2016. The baseline
PsA characteristics were collected and 12 (32.4%) patients had peripheral arthritis, 13 (35.1%) had
axial involvement, 24 (64.9%) had enthesitis, and 13 (35.1%) had dactylitis. Three patients (8.1%)
were treated with methotrexate, 28 (75.7%) with TNF-α blockers, and 6 (16.2%) with IL-17 blockers.
After a month of intermittent fasting, C-reactive protein (CRP) levels decreased from 14.08 ± 4.65 to
12.16 ± 4.46 (p < 0.0001), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) decreased
from 2.83 ± 1.03 to 2.08 ± 0.67 (p = 0.0078), Psoriasis Area Severity Index (PASI) decreased from
7.46 ± 2.43 to 5.86 ± 2.37 (p < 0.0001), and Disease Activity index for PSoriatic Arthritis (DAPSA)
decreased from 28.11 ± 4.51 to 25.76 ± 4.48 (p < 0.0001). Similarly, enthesitis improved after fasting,
with Leeds Enthesitis Index (LEI) decreasing from 2.25 ± 1.11 to 1.71 ± 0.86 (p < 0.0001) and dactylitis
severity score (DSS) decreasing from 9.92 ± 2.93 to 8.54 ± 2.79 (p = 0.0001). Fasting was found to
be a predictor of a decrease in PsA disease activity scores (DAPSA, BASDAI, LEI, DSS) even after
adjustment for weight loss. IL-17 therapy was found to be an independent predictor of decreases in
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LEI after fasting. These preliminary data may support the use of chronomedicine in the context of
rheumatic diseases, namely PsA. Further studies are needed to support our findings.
Keywords: psoriatic arthritis; intermittent fasting; circadian rhythm and biological clock; chronomedicine
1. Introduction
Psoriatic arthritis (PsA) is an inflammatory arthropathy that occurs in up to 30% of people with
psoriasis [1]. PsA is considered to be a member of the spondyloarthritis (SpA) family, whose members
share several pathogenic and therapeutic aspects [2]. The pathogenesis of PsA is not fully understood,
although it is believed to be a result of a complex interplay between genetic background and different
environmental factors such as mechanical stress or dysbiosis [3].
Several studies of different designs have shown that PsA has a serious impact on quality of life and
can be a very destructive and progressive disease [4]. Moreover, it has been found that patients with
PsA have a higher rate of comorbidities, such as cardiovascular diseases, that may affect mortality rates
in these patients [5]. Similar to the SpA spectrum of disorders, enthesitis is a cardinal manifestation
of PsA and has been associated with worse prognostic outcomes of PsA disease [6,7]. Furthermore,
dactylitis is a sometimes disabling PsA-associated manifestation [8]. The introduction of biologic
therapy has revolutionized the management of PsA patients in the clinic. However, other factors,
including those related to diet (such as weight loss and surgical bypass procedures for obesity), may
have a benefit in treating and preventing PsA development.
Ramadan fasting is a religious duty, even though some population demographics such as children,
pregnant or breastfeeding women, travelers, and patients are waived. The fasting in Ramadan consists
of intermittent fasting that is observed from sunrise to sunset and is alternated with moments of
re-feeding [9]. Differently from other fasting and dieting regimens, such as caloric restriction, the
Ramadan fasting follows the circadian rhythm. However, despite this peculiarity, the potential impact
of intermittent fasting on the immune system has been relatively overlooked.
We have previously published a systematic review that has demonstrated contrasting findings
among different studies, although a number of studies showed that intermittent fasting can decrease the
levels of several proinflammatory cytokines levels such as IL-1, TNF, and IL-6 [9]. Other studies found
that fasting can impact on neutrophils function by attenuating the release of myeloperoxidase enzyme,
reduction of the production of leukotrienes, and altering the fatty acid composition of membrane
phospholipids leading to the decrease of inflammatory markers and symptoms [10]. There is very
little data concerning the link of fasting and the activity of specific autoimmune diseases. Recently
we showed beneficial effects of Ramadan fasting on the activity of psoriasis diseases expressed in the
Psoriasis Area Severity Index (PASI) [11]. However, there are no studies assessing the impact of fasting
on PsA disease activity or related disorders including enthesitis and dactylitis. Therefore, this study
aimed to examine prospectively the effect of intermittent fasting during Ramadan on PsA disease
activity, enthesitis and dactylitis.
2. Materials and Methods
2.1. Ethical Approval
The research received ethical approval from the ethical committees of the three medical centers
involved with this study (the San Gallicano’s Dermatological Institute, Rome, Italy; the Dermatology
Unit of the hospital IRCCS Istituto Ortopedico Galeazzi, Milan, Italy; and the Dermatology Unit of
the hospital IRCCS San Donato, Milan, Italy) and was carried out according to the 1964 Helsinki’s
declaration and its subsequent amendments (sub-analysis of the study protocol ID T-ART, date of
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approval 17 July 2014, amended on 10 July 2015). Written informed consent was obtained from each
participant in the study.
2.2. Patients’ Selection and Inclusion
Patients were included in the study from three medical centers (the San Gallicano’s Dermatological
Institute, Rome, Italy; the Dermatology Unit of the hospital IRCCS Istituto Ortopedico Galeazzi, Milan,
Italy; and the Dermatology Unit of the hospital IRCCS San Donato, Milan, Italy). Inclusion criteria were
as follows: (i) age greater than 18 years; (ii) being diagnosed with PsA according to the Classification
for Psoriatic Arthritis (CASPAR) criteria; (iii) planning to fast the whole month of Ramadan; (iv) no
significant difference in the severity of PsA disease among the last two clinical visits (<10% of change
in severity score); v) all the current medications were in the maintenance phase of administration and
not induction phase. Exclusion criteria were defined as the following: (i) pregnancy or breast feeding;
(ii) seropositivity for hepatitis C virus (HCV), hepatitis B virus (HBV), or human immunodeficiency
virus (HIV); (iii) any medical issue preventing the patient from following the fasting.
2.3. Measures and Outcomes
Different biochemical parameters (namely, white blood cells, neutrophils, lymphocytes, red blood
cells, mean corpuscular volume, hemoglobin, platelets, creatinine, urea, aspartate aminotransferase,
alanine aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, and C-reactive protein
or CRP) were collected before and after the Ramadan fasting.
To assess the PsA disease activity, Disease Activity index for PSoriatic Arthritis (DAPSA) was
used. This score includes the assessment of tender joints, swollen joints, CRP levels, the activity of the
disease and the level of pain, with a score of 0–4 for remission, 5–14 low, 15–28 moderate, >28 high
disease activity.
For those with axial involvement detected by spine magnetic resonance imaging (MRI), the Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess any change after fasting.
The score consists of a 0–10 scale measuring discomfort, pain, and fatigue.
Enthesitis severity was assessed by the Leeds Enthesitis Index (LEI), which consists of the
examination of six sites: two sites at each of the lateral epicondyles of the humerus, medial condyles of
the femur, and the insertion of the Achilles’ tendon, with a maximum score of 6.
Dactylitis assessment was done by dactylitis severity score (DSS), which is determined by a scale
of 0–3 for each digit of the hands and feet, with a total score for a patient ranging from 0 to 60.
DAPSA, BASDAI, LEI, and DSS were evaluated by two different independent board-certified
rheumatologists and the average number of each tool was obtained. A third rheumatologist was
consulted in cases where there was a significant difference in the computed scores between the two
rheumatologists (greater than 5%). Severity and extent of psoriasis was assessed by Psoriasis Area
Severity Index (PASI), which was calculated by a dermatologist, with a maximum score of 72.
All scores were calculated 1–3 days before the beginning of the Ramadan fasting, and 1–3 days
after the end of the month of Ramadan.
2.4. Statistical Analysis
Before handling or analyzing any data, figures were visually inspected in order to capture any
potential outlier. Normality of data distribution was checked by conducting the Shapiro-Wilk’s test.
This test was preferred to other tests, given the small sample size.
Data were computed as means ± standard deviations for continuous variables, whereas they
were expressed as percentages in the case of categorical parameters.
Student’s t-test for paired samples was applied to compute the mean differences before and after
the Ramadan fasting.
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Pairwise Hodges–Lehmann (H-L) median differences were also computed. Multiple regression
analyses (using stepwise and enter approach) were conducted in order to shed light on the independent
predictors of changes in the different scores.
All statistical analyses were carried out using the commercial software “Statistical Package for
the Social Sciences” (SPSS for Windows, version 24, IBM, Armonk, NY, USA) and all graphs were
generated using the commercial software MedCalc Statistical Software version 18.11.3 (MedCalc
Software bvba, Ostend, Belgium; https://www.medcalc.org).
For all analyses, figures with a p-value less than 0.05 were considered to be statistically significant.
3. Results
3.1. Study Population
Out of 40 patients, 37 (23 females, 14 males) took part in the present study (from 6 June 2016 to
5 July 2016, with a length of fasting of approximately 17 h) (Table 1).
Table 1. Main characteristics of the study population.
Parameter Value
Age (years) 43.32 ± 7.81 (median 43)
Gender (%)
Male 14 (37.8%)
Female 23 (62.2%)
BMI (kg/m2) 26.16 ± 1.59
Disease duration (years) 7.59 ± 3.78 (median 8)
Family history positive for PsA 15 (40.5%)
Country of origin
Egypt 10 (27.0%)
Morocco 6 (16.2%)
Algeria 5 (13.5%)
Turkey 5 (13.5%)
Israel 3 (8.1%)
Kurdistan 3 (8.1%)
Afghanistan 2 (5.4%)
Cyprus 2 (5.4%)
Jordan 1 (2.7%)
Enthesitis 24 (64.9%)
Dactylitis 13 (35.1%)
Axial involvement 13 (35.1%)
Peripheral arthritis 12 (32.4%)
Treatment
Methotrexate 3 (8.1%)
TNF-α blockers 28 (75.7%)
IL-17 blockers 6 (16.2%)
Abbreviations: BMI, body mass index; IL-17, interleukin-17; PsA, psoriatic arthritis; TNF-α, tumor necrosis
factor alpha.
Three patients were excluded due to medical issues that prevented them from continuing fasting
(one had pneumonia and was referred to internal medicine, one had gastroenteritis, and the last one
had renal failure). The mean age was 43.32 ± 7.81 years (median 43 years) and the mean BMI was
26.16 ± 1.59 kg/m2 (median 26 kg/m2). Twelve subjects (32.4%) reported a normal weight whereas 25
(67.6%) were overweight.
The PsA disease duration was on average 7.59 ± 3.78 years (median 8 years). Fifteen patients
(40.5%) had a positive family history for PsA. All patients were treated with stable dose therapy
only, and 3 patients (8.1%) were treated with methotrexate (range 15–20 mg/week), 28 (75.7%) with
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TNF-α blockers (11 treated with Etanercept 50 mg/week, 11 with Adalimumab 40 mg/week, 3 with
Golimumab 50 mg/4 weeks, and 3 with Certolizumab 200 mg/2 weeks), and 6 (16.2%) with IL-17
blockers (4 treated with Secukinumab 150 mg/4 weeks, and 2 with Ixekizumab 80mg/4 weeks).
With regard to PsA disease features at baseline, 12 (32.4%) had peripheral arthritis, 13 (35.1%) had
axial involvement, 24 (64.9%) had enthesitis, and 13 (35.1%) had dactylitis.
3.2. Impact of Intermittent Fasting on Patient Weight
After the Ramadan fasting, the average weight loss was not different from the one observed
before fasting. Twenty-nine patients (78.4%) did not report any change in weight, whereas 4 subjects
(10.8%) gained 1 kg and 1 individual (2.7%) gained 2 kg. Three subjects (8.1%) lost 1 kg.
3.3. Impact of Intermittent Fasting on Biochemical Parameters
The Ramadan fasting had no impact on any biochemical parameter studied, except for CRP
(Table 2).
Table 2. Biochemical parameters before and after the Ramadan fasting.
Parameter Before Fasting After Fasting
WBC (N/µL) 7850 ± 430 7750 ± 510
Neutrophils (109/L) 5.4 ± 0.8 5.4 ± 0.6
Lymphocytes (109/L) 2.7 ± 0.4 2.8 ± 0.4
RBC (106/µL) 5.6 ± 1.2 5.7 ± 1.1
MCV (fL) 89.8 ± 2.3 90 ± 2.1
Hb (g/dL) 14.8 ± 1.3 14.7 ± 1.4
PLT (1,000/µL) 215 ± 32 216 ± 28
Creatinine (mg/dL) 0.7 ± 0.1 0.7 ± 0.1
Urea (mg/dL) 7.3 ± 0.9 6.9 ± 1.2
AST (IU/L) 37 ± 5.2 38 ± 4
ALT (IU/L) 35 ± 8.3 36 ± 6.7
GGT (IU/L) 26 ± 5.6 26 ± 4
ALK (IU/L) 48 ± 8 47 ± 6.4
CRP (mg/dL) 14.1 ± 4.7 12.2 ± 4.5
Abbreviations: WBC, white blood cells; RBC, red blood cells; MCV, mean corpuscular volume; Hb, hemoglobin;
IU, international units; PLT, platelets; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT,
gamma-glutamyl transferase; ALK, alkaline phosphatase; CRP, C-reactive protein.
CRP was the only biochemical parameter for which a statistically significant change before and
after the Ramadan fasting could be detected. Indeed, CRP levels decreased from 14.08 ± 4.65 to
12.16 ± 4.46 (mean difference −1.92 (95% CI, −2.38 to −1.46), p < 0.0001; H-L median difference −2
(95%CI, −2.5 to −1.5), p < 0.0001) (Figure 1).
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3.4. Impact of Intermittent Fasting on PsA Disease Activity Scores, Enthesitis and Dactylitis
Similarly, DAPSA decreased from 28.11 4.51 to 25.76 4.48 (mean difference −2.35 (95% CI, −3.03
to −1.67), p < 0.0001; H-L median difference −2 (−2.5 to −1.5), p < 0.0001) (Figure 2).Nutrients 2019, 11, x FOR PEER REVIEW 6 of 12 
 
 
Figure 2. Change in Disease Activity Index for PSoriatic Arthritis (DAPSA) score after intermittent 
fasting. 
BASDAI decreased from 2.83 ± 1.03 to 2.08 ± 0.67 (mean difference −0.76 (95% CI, −1.14 to −0.36), 
p = 0.0015; H-L median difference −1 (95% CI, −1 to −0.5), p = 0.0078) (Figure 3). 
 
Figure 3. Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score after 
intermittent fasting. 
PASI decreased from 7.46 ± 2.43 to 5.86 ± 2.37 (mean difference −1.59 (95% CI, −1.87 to −1.32), p < 
0.0001; H-L median difference −1.5 (95% CI, −2 to −1.5), p < 0.0001) (Figure 4).  
 
Figure 4. Change in Psoriasis Area Severity Index (PASI) after intermittent fasting. 
Figure 2. Change in Disease Activity Index for PSoriatic Arthritis (DAPSA) score after
intermittent fasting.
BASD I decreased from 2.83 ± . to 2.08 ± 0.67 (mean diff rence −0.76 (95% CI, −1.14 to
−0.36), p = .0015; H-L median diff rence −1 (95% CI, −1 to −0.5), p = 0.0078) (Figure 3).
Nutrients 2019, 11, x FOR PEER REVIEW 6 of 12 
 
 
Figure 2. Change in Disease Activity Index for PSoriatic Arthritis (DAPSA) score after intermittent 
fasting. 
BASDAI decreased fro  2.83 ± 1.03 to 2.08 ± 0.67 ( ean difference −0.76 (95  CI, −1.14 to −0.36), 
p = 0.0015; -L edian difference −1 (95  CI, −1 to −0.5), p = 0.0078) (Figure 3). 
 
Figure 3. Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score after 
intermittent fasting. 
PASI decreased fro  7.46 ± 2.43 to 5.86 ± 2.37 ( ean difference −1.59 (95  CI, −1.87 to −1.32), p < 
0.0001; -L edian difference −1.5 (95  CI, −2 to −1.5), p < 0.0001) (Figure 4).  
 
Figure 4. Change in Psoriasis Area Severity Index (PASI) after intermittent fasting. 
Figure 3. Change in Bath Ankylosing Spondylitis e ctivity Index (BASDAI) score after
intermittent fasting.
PASI decreased from 7.46 ± 2.43 to 5.86 . ( ean diff rence −1.59 (95% CI, −1.87 to −1.32),
p < 0. 001; H-L medi rence −1.5 (95% CI, −2 to −1.5), p < 0.0001) (Figure 4).
Nutrients 2019, 11, x FOR PEER REVIEW 6 of 12 
 
 
Figure 2. Change in Disease Activity Index for PSoriatic Arthritis (DAPSA) score after intermittent 
fasting. 
BASDAI decreased from 2.83 ± 1.03 to 2.08 ± 0.67 (mean difference −0.76 (95% CI, −1.14 to −0.36), 
p = 0.0015; H-L median difference −1 (95% CI, −1 to −0.5), p = 0.0078) (Figure 3). 
 
Figure 3. Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score after 
intermittent fasting. 
PASI decreased from 7.46 ± 2.43 to 5.86 ± 2.37 (mean difference −1.59 (95% CI, −1.87 to −1.32), p < 
0.0001; H-L median difference −1.5 (95% CI, −2 to −1.5), p < 0.0001) (Figure 4).  
 
Figure 4. Change in Psoriasis Area Severity Index (PASI) after intermittent fasting. 
Figure 4. Change in Psoriasis Area Severity Index (PASI) after intermittent fasting.
Nutrients 2019, 11, 601 7 of 11
LEI decreased from 2.25 ± 1.11 to 1.71 ± 0.86 (mean difference −0.54 (95% CI, −0.76 to −0.33),
p < 0.0001; H-L median difference -0.5 (95% CI, −1 to −0.5), p = 0.0002) (Figure 5).
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Multivariate regression analyses (enter approach) investigating the main covariates associated 
with improvements in clinical scores after fasting found no significant independent predictors 
except for therapy, which was found to be associated with decreases in LEI (Table 3).  
These were greater in those treated with IL-17 blockers and lower in those under methotrexate. 
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Table 3. Multivariate regression analyses investigating the main covariates associated with
improvements in clinical scores after fasting.
Independent Variables Coefficient Standard Error (SE) t p-Value rpartial rsemipartial
Delta BASDAI
(Constant) 5.04
Age −0.05 0.03 −1.63 0.1480 −0.52 0.48
Therapy 0.58 0.50 1.15 0.2883 0.40 0.34
Gender 0.33 0.51 0.65 0.5397 0.24 0.19
BMI −0.14 0.15 −0.95 0.3732 −0.34 0.28
Delta CRP
(Constant) 3.98
Age −0.03 0.03 −0.83 0.4132 −0.15 0.14
Therapy −0.46 0.53 −0.86 0.3942 −0.15 0.15
Gender 0.48 0.57 0.85 0.3997 0.15 0.15
BMI −0.01 0.18 −0.043 0.9658 −0.01 0.01
Delta DAPSA
(Constant) 12.06
Age −0.05 0.05 −1.10 0.2785 −0.19 0.19
Therapy −0.66 0.78 −0.86 0.3991 −0.15 0.14
Gender 0.94 0.83 1.14 0.2627 0.20 0.19
BMI −0.25 0.27 −0.93 0.3601 −0.16 0.16
Delta Dactylitis Severity Score
(Constant) −4.13
Age 0.01 0.02 0.41 0.6845 0.07 0.07
Therapy −0.32 0.30 −1.04 0.3063 −0.18 0.17
Gender −0.52 0.32 −1.60 0.1186 −0.27 0.26
BMI 0.24 0.11 2.28 0.0293 0.37 0.37
Delta Leeds Enthesitis Index
(Constant) −1.71
Age 0.02 0.01 1.08 0.2939 0.24 0.21
Therapy 0.57 0.26 2.22 0.0390* 0.45 0.44
Gender −0.19 0.27 −0.72 0.4833 −0.16 0.14
BMI 0.02 0.08 0.23 0.8212 0.05 0.04
Abbreviations: BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index); CRP,
C-reactive protein; DAPSA, disease activity index for psoriatic arthritis.
4. Discussion
This is the first study to demonstrate that intermittent fasting has beneficial effects on PsA disease
expressed by DPSAI, BASDAI, enthesitis, and dactylitis. This benefit was not linked to weight loss,
which remained stable in the cohort throughout the study. Indeed, even after adjusting for weight
change, the benefit of fasting on PsA disease activity scores remained statistically significant.
Dietary habits have been found to have a significant impact on human health, affecting the risk
for hypertension and cardiovascular diseases, as well as influencing the risk of developing malignant
conditions and impacting on mortality [12]. Nutritional status and dietary compounds have long
been recognized as important factors in the alteration of immune system activity. Indeed, salt has
been reported to enhance inflammation via the increase of IL-17A levels and reduction of T regulatory
function [13]. By contrast, other dietary compounds such as curcumin and capsaicin in spicy foods and
resveratrol contained in chocolate are able to attenuate the immune system reactions and activity by
increasing M2/M1 macrophages and also B regulatory cells function [13]. Although with inconclusive
results, the so-called “Western diet” has been linked with an increased risk of autoimmune diseases
such as Crohn’s diseases and ulcerative colitis [14]. On the other hand, higher consumption of extra
virgin olive oil was found to be associated with a lower psoriasis severity [15]. This is believed to be
attributed to oleocanthal, a phenolic compound contained in extra virgin olive oil that is known to have
anti-inflammatory effects. However, very few studies have addressed the effect of fasting subtypes on
the immune system activity. An interesting study assessed the impact of a 36-h fasting period followed
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by a 4-h refeeding period on different components of the immune system in both healthy elderly and
young adult volunteers [16]. The study found a significant decrease in the percentage of T-cells subsets
in both study populations and this decrease persisted after the refeeding. This may explain some of
the beneficial effects induced by fasting in PsA patients, as T-cells are a major player in the disease.
The treatment of PsA can be highly challenging, and very often there is the need for more than
one therapeutic agent to control disease. Obesity has been widely linked to psoriasis and PsA [17,18].
Another study has shown that BMI at the age of 18 years but not the current BMI is linked with an
increased risk of the development of PsA [19]. It has also been suggested that treatment of obesity may
lead to a better management of PsA [20].
However, in our study, fasting led to improvement in PsA disease activity scores, enthesitis, and
dactylitis regardless of the change in the patients’ weight, which may support that the fasting process
itself can affect the immune system activity. This is not surprising, as it has already been reported that
intermittent fasting can induce reduction in the proinflammatory cytokines, increase the function of T
regulatory cells, and decrease the activity of Th17 cells, all of which are known to be involved in PsA
pathogenesis [9].
In man, circadian rhythms are biological processes that synchronize to the rotation of the Earth
or a 24-h period. Numerous events can cause disruptions of the circadian clock, such as jet lag
(de-synchrony), light/darkness, as well as night shift working [21–23].
Circadian rhythms are involved in the regulation of many activities including sleep, feeding times,
energy metabolism, as well as both the endocrine and the immune systems [23]. When the circadian
rhythm is altered, such as that caused by sleep and feeding, this has been linked to the development of
multiple immunological disorders such as rheumatoid arthritis, cardiovascular disease, asthma, and
atopic dermatitis [24,25].
During fasting, such as Ramadan, disturbances and alterations in sleep patterns are commonly
observed [26]. However, whether Ramadan causes disturbances to circadian rhythm is heavily
debated [27]. The majority of immune cells express circadian clock genes [28]. The circadian rhythm in
immune cells is associated with cytokine/chemokine release, cell migration, phagocytosis, and cytolytic
activity. Circadian disruption has been extensively studied in animal models, by inducing ‘chronic
jet let’ (regular shifts of light), and this was found to induce negative effects on immune cell function
and lead to increased mortality [29,30]. There are also multiple research lines implicating circadian
rhythm with the closely related psoriasis. Psoriasis is associated with sleep disorders [31], moreover,
in a mouse model of psoriasis, circadian clock genes were found to regulate skin inflammation [32].
It also important to mention that during Ramadan, patients tend to administer their drugs during
the night and this may have beneficial effects, as several studies have suggested that bedtime or night
doses compared with morning administration can lead to a better effect of the drug [33–35].
However, our study has several limitations that should be acknowledged. Firstly, our study
had a small sample size due to the extreme difficulty of recruiting patients with PsA that fast the
whole month and were interested in taking part in the study. One month may be a short period to
observe all the potential effects of intermittent fasting on rheumatic disease activity and therefore
longer observation time frames are warranted.
A further limitation was the inability to monitor potential dietary habit changes of the individuals,
which can significantly impact on the disease control. As fasting is normally followed by significant
changes in the daily diet, there may be dietary factors with the potential to impact the PsA disease
activity that should be addressed in future studies.
5. Conclusions
In conclusion, intermittent fasting was shown to have beneficial effects on PsA disease activity,
including PsA-related disorders such as enthesitis and dactylitis, regardless of the implicated drug
therapy. These findings may be translated into new management strategies of PsA patients. However,
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larger studies are needed to replicate our findings, and longer observation time frames (for instance,
studying several months of fasting) are recommended.
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